top of page

AMG 334 significantly reduces monthly migraine days in study

Novartis and Amgen have announced positive first results from the Phase II 20120295 study, investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page